Endocrinology Roundup: Stem Cell Infusion Slashes Fractures, Testosterone Debate and Links Between Bone Density and Cognition
A small stem cell trial showed a 94% drop in fragility fractures; new GLP-1 and dual-agonist data shift the obesity landscape; regulators, courts, and insurers weigh in on testosterone and GLP-1s.
Several developments in endocrinology this week could influence treatment decisions for osteoporosis, obesity, and menopausal symptoms while raising fresh questions about long-term risks and policy. A tiny but striking trial showing a dramatic fracture decline after a single stem cell infusion sits alongside competitive data on new weight-loss drugs and ongoing debates about testosterone therapy for women.
Key clinical findings
A single infusion of stem cells produced a 94% reduction in fragility fractures over two years in a study of 10 women with advanced osteoporosis, according to a report in Cell. The trial’s small size means the result is preliminary, but the magnitude of the effect has generated interest in regenerative approaches to severe bone loss.
In obesity and diabetes research, Novo Nordisk’s investigational low-dose CagriSema led to greater weight loss than tirzepatide (Mounjaro) 5 mg in a phase III trial of adults with type 2 diabetes (12.4% vs. 9.1%). Roche’s dual agonist enicepatide produced 15.5% weight loss at 48 weeks in a phase II study of adults with obesity and diabetes.
Imaging research adds another layer: deep learning analysis of noncontrast chest CT scans found that lower thoracic vertebral bone mineral density (BMD) was associated with faster cognitive decline, with the relationship strongest among adults with diabetes, according to Radiology.
Therapy debates, lawsuits and policy moves
The FDA convened an expert panel to evaluate the evidence for testosterone therapy in menopausal women, reflecting growing clinical controversy about benefits and risks. Relatedly, the Pentagon has resumed a contentious program to test troops’ testosterone levels after a brief pause, Reuters reported.
Legal and policy developments include Justice Department actions that resulted in New York University Langone Hospitals and the University of Pittsburgh Medical Center agreeing to stop providing gender-affirming care for minors and paying more than $9 million in combined fines. Meanwhile, dozens of patients have sued manufacturers of GLP-1 drugs, alleging inadequate warnings about a rare sudden vision loss called non-arteritic anterior ischemic optic neuropathy.
Coverage is shifting too: the Washington Post reported that employer-sponsored health plans are expected to adjust how they cover GLP-1 medications as their use expands. Real-world data continue to shape prescribing and outcomes—one observational study of 246 adults with type 1 diabetes linked worsening time-in-target glucose range with a higher five-year incidence of microvascular complications (Journal of Clinical Endocrinology & Metabolism).
Other notable items
The Endocrine Society announced the 13 winners of its 2027 Laureate Awards. In comparative-effectiveness research, a target trial emulation published in The BMJ found SGLT2 inhibitors and GLP-1 receptor agonists significantly reduced the risk of renal function decline versus DPP-4 inhibitors in adults with type 2 diabetes and albuminuria. And in a widely reported personal account, Illinois Governor J.B. Pritzker said he lost 80 pounds after using a GLP-1 medication (People).
Taken together, these reports highlight rapid movement across multiple fronts in endocrinology—novel biologic approaches to bone disease, intensifying competition among metabolic drugs, and continuing scrutiny of hormonal therapies and drug safety.